NANO-X IMAGING LTD - Ordinary Shares (NNOX)

NEW YORK, April 21, 2026 (GLOBE NEWSWIRE) -- Pomerantz LLP is investigating claims on behalf of investors of Nano-X Imaging Ltd. (“Nano-X” or the “Company”) (NASDAQ: NNOX). Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, ext. 7980.

Howard’s nationwide reach across healthcare and public sector markets expands Nanox’s U.S. channel partner network to additional customer segments

Advanced commercialization in the US, signing multiple new customer and distribution agreements for Nanox.ARC and accelerated activities around Nanox.AI

Enhancing emergency triage imaging with Nanox.ARC to improve efficiency and lower radiation dose

Fourth distribution agreement of 2026 strengthens Nanox’s U.S. commercial momentum

PETACH TIKVA, Israel, April 06, 2026 (GLOBE NEWSWIRE) -- NANO-X IMAGING LTD ("Nanox" or the "Company", Nasdaq: NNOX), an innovative medical imaging technology company, today announced that it will report its financial results for the quarter ended December 31, 2025, before market open on Monday, April 20, 2026. Erez Meltzer, Chief Executive Officer and Acting Chairman, and Ran Daniel, Chief Financial Officer, will host a conference call to review these results and provide a business update beginning at 8:30 a.m. ET.

New regional partnership strengthens Nanox’s presence and service support across outpatient imaging settings in Colorado, Wyoming and the western parts of Kansas and Nebraska

Distribution agreement to enhance channel partner expansion across five U.S. states

NEW YORK CITY, NY / ACCESS Newswire / March 26, 2026 / Investor Summit Group is excited to share that the presentations from Q1 Virtual Conference are now available on-demand. If you missed the live event, now's your chance to catch up at your own pace.

EQNX::TICKER_START (NASDAQ:VWAV),(NASDAQ:NNOX),(NASDAQ:SWKS),(NASDAQ:ADI),(NASDAQ:VIAV) EQNX::TICKER_END

NEW YORK, NY / ACCESS Newswire / March 20, 2026 / The Investor Summit today announced the lineup of public companies scheduled to present at its upcoming Virtual March 25-26, 2026 event.

Agreement with Imperial Imaging strengthens Nanox’s commercial rollout across the orthopedic-rich segment in six U.S. Southeast states.

Collaboration with Intec SRL drives commercial expansion of 3D medical imaging across a high-growth private healthcare market

Collaboration with Adriamed drives commercial expansion and strengthens Nanox’s regional leadership

Nano-X Imaging (NASDAQ: NNOX) entered a securities purchase agreement with a single institutional investor to sell 3,826,530 ordinary shares in a registered direct offering expected to generate approximately $15 million in gross proceeds, with Titan Partners Group, a division of American Capital Partners, serving as sole placement agent. Closing is expected on or about Nov. 25, 2025, and the company plans to use the net proceeds for working capital and general corporate purposes.

Althea France, part of one of Europe's largest independent medical technology services providers, to distribute CE-marked Nanox.ARC system across French healthcare sector

Nanox’s HealthOST and HeathVCF recommended for use in UK National Health Service hospitals for a three-year period as the use of AI solutions in bone disease is evaluated

PETACH TIKVA, Israel, Nov. 23, 2025 (GLOBE NEWSWIRE) -- NANO-X IMAGING LTD (“Nanox” or the “Company”, Nasdaq: NNOX), an innovative medical imaging technology company, today announced that it has entered into a securities purchase agreement with a single institutional investor for the purchase and sale of 3,826,530 ordinary shares (“Common Stock”) in a registered direct offering. The offering is expected to result in gross proceeds of approximately $15 million, before deducting offering expenses. The closing of the offering is expected to occur on or about November 25, 2025, subject to the satisfaction of customary closing conditions.

Management to host conference call and webcast Thursday, November 20, 2025, at 8:30 AM ET

PETACH TIKVA, Israel, Nov. 19, 2025 (GLOBE NEWSWIRE) -- NANO-X IMAGING LTD (“Nanox” or the “Company”, Nasdaq: NNOX), an innovative medical imaging technology company, today announced that the parties have agreed on the terms and conditions pursuant to which Nanox will acquire VasoHealthcare IT Inc. (“VHC IT”) from Vaso Corporation (“Vaso”) (OTCQX: VASO), subject to certain conditions.

3DR® Labs to Offer Nanox.AI’s FDA-Cleared Imaging Solutions to Its Network of More Than 1,800 Hospitals and Imaging Centers Across the U.S.

Olympe Imagerie to deploy Nanox.ARC at Paris-area Hospital Privé Jacques Cartier MASSY for lung cancer screening applications

PETACH TIKVA, Israel, Nov. 07, 2025 (GLOBE NEWSWIRE) -- NANO-X IMAGING LTD ("Nanox" or the "Company", Nasdaq: NNOX), an innovative medical imaging technology company, today announced that it will report its financial results for the quarter ended September 30, 2025, before market open on Thursday, November 20, 2025. Erez Meltzer, Chief Executive Officer and Acting Chairman, and Ran Daniel, Chief Financial Officer, will host a conference call to review these results and provide a business update beginning at 8:30 a.m. ET.